Topic resource collection
Approved comparison material connected to this topic.
1378 resourcesRead both sides
Understanding the trade-offs between different 5-Amino-1MQ storage methods is crucial for making informed decisions in your lab. Here's a quick comparison: Freezer (Lyophilized) Powder (unopened) -20°C to -80°C 2-5+ years Maximum…
Tirzepatide (15mg weekly) Dual GLP-1/GIP receptor agonist. Delays gastric emptying, extends satiety, potentiates insulin secretion 20.9% at 72 weeks (SURMOUNT-1) GI side effects in 40–50% during titration; pancreatitis risk <1% F…
Every peptide mentioned here is available as a research-grade compound through Real Peptides' full peptide collection. We mean this sincerely: the purity and sequencing accuracy matter more in cessation protocols than in almost a…
Tirzepatide (dual GLP-1/GIP) Incretin receptor agonist. Slows gastric emptying, enhances insulin sensitivity, suppresses appetite via hypothalamic signaling 20.9% mean body weight reduction at 72 weeks (SURMOUNT-1, n=2,539). High…
Survodutide Dual GLP-1/glucagon agonist 12.5–14.7% Nausea (40%), diarrhea (28%), elevated heart rate (15%) Fastest fat oxidation due to hepatic glucagon signaling. Best for patients who plateau on GLP-1 monotherapy Mazdutide GLP-…
GLP-1 Agonists (Semaglutide, Tirzepatide) Slows gastric emptying, extends satiety signaling, delays ghrelin rebound 15–22% body weight over 68–72 weeks Addresses age-related leptin resistance and compensatory hunger mechanisms Na…
Thymalin Immune modulation. Upregulates CD4+ T-cells, suppresses neuroinflammatory cytokines (TNF-α, IL-6) Indirect. Peripheral immune signals cross BBB; peptide itself does not 5–10 mg SC daily × 10–20 days (human equivalent ~0.…
The best peptides for Alzheimer's prevention work through immune modulation rather than direct amyloid clearance. Thymalin, a thymic peptide, upregulates CD4+ T-cell function and suppresses pro-inflammatory cytokines (TNF-α, IL-6…
Counterfeit research peptides cost labs more than money. They cost months of invalid data. A 2024 analysis published by the Journal of Pharmaceutical Sciences found that 37% of peptides purchased from unverified suppliers contain…
BPC-157 VEGF upregulation, angiogenesis, nitric oxide pathway activation 250–500mcg daily subcutaneous, localized near injury site 28 days refrigerated in bacteriostatic water; <72 hours in sterile water Days 14–56 (proliferative…
CoA Third-Party Lab ISO/IEC 17025-accredited lab listed by name, accreditation number searchable in ILAC database Generic lab name, missing accreditation, or non-existent lab reference Search accreditation number at ilac.org or c…
BPC-157 VEGF upregulation → angiogenesis Phase II diabetic ulcer trial: 42% faster healing vs standard care (University of Split, 2025) Topical or subcutaneous injection near injury site 5–7 days at 2–8°C once reconstituted Most …
The table below compares three validated peptide categories used in metabolic research protocols. Each operates through distinct mechanisms and timelines. Growth Hormone Secretagogues (MK 677, CJC-1295) Bind to ghrelin receptors …
SS-LUP-332 2–8°C 28 days No. Ice crystals shear peptide bonds Bacteriostatic water (0.9% benzyl alcohol) Short half-life and oxidation-prone methionine residues make this the most temperature-sensitive PPARδ agonist. Strict refri…
Conservative Daily 50mcg Morning (fasted) Once daily Minimal. Below functional threshold for most individuals Dose too low to achieve meaningful myostatin inhibition; reserve for preliminary tolerance assessment Standard Single-D…
SS-LUP-332 ERRα/γ agonist. Forces mitochondrial shift to fat oxidation Fatigue (20–25%), GI disturbance (12–15%), transient enzyme elevation (15–20%) Transient AST/ALT increase, resolves in 10–14 days, no structural damage Modera…
2-week acute protocol 50mg/day Measurable within 10–14 days via indirect calorimetry Increased ATP/ADP ratio, reduced lactate accumulation during exertion Short-term metabolic reset; often used before extended fasting or caloric …
Here's the honest answer: SS-LUP-332 appears safe based on current evidence. Meaning it doesn't cause irreversible organ damage, systemic toxicity, or life-threatening adverse events at therapeutic doses. But safety and tolerabil…
SLU-PP-332 0.4 µM <5% at 10 µM 2.8–3.5× in skeletal muscle Metabolic disease models, mitochondrial dysfunction studies Selective ERRα/γ agonist. No TRβ binding at therapeutic doses GSK4716 1.0 µM (ERRγ-selective) ~30% at 10 µM 1.…
SLU-PP-332's unique value lies in the separation between acute activation and long-term adaptation. Acute activation. The initial ERRα binding and transcriptional upregulation. Happens within 1–2 hours and can be measured through…